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symptoms did not provide additive predictive information for future shocks among ICD 
patients. More data is needed to explore further the elevation in risk among Class Ill-IV 
CHF patients. 
1064-Z implication of MADIT-II on Unselected Patients 
Following an Acute Myocardial Infarction 
Steen 2. Abildstrom, Christian Tarp-Pedersen, Lars Kober, National Institute of Public 
Health, Copenhagen, Denmark, Rigshospitalet, Copenhagen, Denmark 
Results: Qf the 5963 register patients alive at discharge 1009 patients (17%) fulfilled the 
MADIT-II criteria. Over a mean follow-up of 2.0 years 160 patients experienced SCD and 
227 non-sudden cardiac death. BBB was present in only 16% of the patients. BBB was 
associated with an increased risk of SCD, hazard ratio 1.50, P<O.O5. 
Conclusion: The frequency of sudden death in unselected Ml patients eligible for Madit II 
is high and we further confirm the increased potential of benefit in patients with bundle 
Background: In the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) the 
prevalence of increased QRS interval (x0.12 set) was 50%. 
branch block. Bundle branch block is much more rare in unselected patients than in 
Increased QRS interval was associated with a trend towards an increased relative risk 
reduction of ICD treatment. We have therefore studied the prevalence of bundle branch 
patients enroled into Madit Il. 
block (BBB) in consecutive patients with myocardial infarction (Ml) eligible for MADIT-II 
and the risk of sudden cardiac death in patients eligible for MADIT-II. 
Methods: Consecutive Ml patients screened for TRACE in 1990.1992 were entered into 
a registry. MADIT-II selection criteria were applied (ejection fraction <=30%, NYHA func- 
tional class I to Ill). Sudden cardiac death (SCD) was defined as cardiovascular death 
within one hour of symptoms. The hazrad ratio was estimated by Cox regression analy- 
sis. 
1064-3 B-Blocker Reduces the Incidence of Appropriate 
Defibrillator Therapy in Patients With Congestive Heart 
Failure Secondary to Idiopathic Dilated 
Cardiomyopathy 
w Rlchard G. Trohman, Janet Haw, David G. Benditt, University of Minnesota, 
Minneapolis, MN, Rush-Presbyterian-St Luke’s Medical Center, Chicago, IL 
Background: pBlockers (BB) have been shown to reduce the total mortality and sudden 
cardiac death rates in patients with congestive heart failure (CHF). However, the effects 
of BB on the incidence of defibrillator (ICD) therapy in patients with CHF secondary to 
idiopathic dilated cardiomyopathy (IDCM) remain unknown. 
Methods and Results: Eighty-two patients (aged 51516 years) with IDCM who were 
treated with ICDs were enrolled in this study. Their left ventricular ejection fraction 
(LVEF) was 25*9%. These patients were regularly followed for a period of up lo 60 
months (mean 24 months). These patients received frequent appropriate (39%) and 
inappropriate (35%) ICD therapy. The first appropriate ICD therapy occurred at 7.6 
months (median). There was no significant difference between patients on (n=35) and ofl 
BB III age (50*17 vs 52*15 years, p>O.O5). LVEF (27+10% vs 24+6%, p>O.O5), or inci- 
dence of documented spontaneous or inducible sustained ventricular tachycardia I fibril- 
lation before implantation (39% vs 37%, p>O.O5). Fewer patients on BB were treated with 
amiodarone (14% vs 34%. p = 0.07). The incidence of appropriate ICD therapy was sig- 
nificantly lower in patients on BB than those off BB (26% vs 49%, log rank ~~0.05; Fig- 
ure). BB therapy was associated with a 47% reduction in appropriate ICD therapy in 
these patients. 
Conclusion : BB therapy may substantially reduce the incidence of appropriate ICD ther- 
apy in patients with CHF secondary to IDCM. 
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1064-4 Prevalence of Patients With Myocardial Infarction and 
Reduced Left Ventricular Ejection Fraction: Impact of 
MADIT-II Study in the General Population 
Param P. Sharma, Hector Osorio, Robert Greenlee, John Hayes, Peter N. Smith, Kelley 
P. Anderson, Humberto J. Vidaillet, Marshfield Clinic, Marshfield, WI 
Background: The second Multicenter Automatic Defibrillator Implant&ion trial (MADIT II) 
showed that defibrillators reduce all-cause mortality in patients with myocardial infarction 
(Ml) and low left ventricular ejection fraction (LVEF530). Precise estimates of the preva- 
lence of patients who meet MADIT II criteria could assist the assessment of the clinical 
and financial impact of the trial results. 
Methods: We used the resources of the Marshfield Epidemiological Study Area (MESA), 
a well defined geographic region in which Marshfield Clinic and St. Joseph’s hospital pro- 
vide nearlv all health care amona its 60.000 residents. Codes 410-410.92 from the gth 
edition of International Classification of Diseases were used to screen among current 
adult I> 21 vears) MESA residents that have survived a Ml between Janualv 1979 and ,_ _ 
February 2002. The entire medical record of each potential case was then reviewed to 
confirm MADIT II eligibility criteria: documented Ml and LVEF ( 30 %. Population preva- 
lence was calculated by age and gender using established MESA population denomina- 
tors. 
Results: Qf 1221 adults identified in the screening as having survived a MI, 1126 (92%) 
were confirmed by review of medical records. In those remaining, 112 (10%) pattents 
were shown to have an LVEF 5 30%. The 112 patients include 77 (69%) men and 71 
(63%) that are age 75 or older. Among adult MESA residents. the overall population 
prevalence of surviving an Ml and having an LVEF -< 30 % is 2.6 per 1,000 individuals 
(95% confidence interval 2.1-3.1). The prevalence per 1,000 was 3.6 among men and 
Conclusions: In MESA, nearly 10% of all patients with hlstory of a Ml meet MADIT II crite- 
1.6 among women. Prevalence rates ranged from cl per 1,000 among those ~55 years 
ria for defibrillator implantation. If our findings were applicable to the entire US popula- 
tion, we estimate there are 460,000 individuals in the United States that may benefit from 
old lo 21.7 per 1,000 in persons ~65 years. 
this technology. Further research is needed to determine whether the benefits experi- 
enced by the MADIT II study patients are generalizable to all individuals in the general 
population who meet the study criteria. 
1064-5 Are the Results of the Multicenter Automatic 
Defibrillator Implantation Trial-II Applicable to Patients 
Seen at a Tertiary Referral Center? 
Sana M. Al-Khatib. Yun Li, Kevin Anstrom. Eric Peterson, James Jollis, Christopher 
O’Connor, Kerry L. Lee, Linda Shaw. Robelt M. Califf. Duke University Medical Center, 
Durham, NC 
Background: Some physicians have questioned the applicabtllty of the results of the 
recently published Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) to 
their patients. The purpose of this study is to determine the generalizability of the MADIT- 
II results. 
Methods: We used the Duke Cardiovascular Disease Database that has systematically 
collected the baseline characteristics and long-term follow-up of all patients who undergo 
a cardiac catheterization at our institution. We explored the baseltne characteristics of 
patients who met the MADIT-II inclusion criteria and examined their su~wal without an 
implantable cardioverter defibrillator (ICD). We estimated their life expectancy by assum- 
ing a Weibull distribution. The impact of ICD’s on life expectancy was determined by the 
relative risk reduction observed in MADIT-II assuming that the survival benefit from an 
ICD is constant over time. 
Results: Of patients undergoing cardiac catheterization between 1966 and 2001, 1392 
(2.7%) met the MADIT-II inclusion criteria. Our patients were similar to the MADIT-II 
patients in age (64 years, 25th and 75th percentiles of 55 and 71 years), ejectlon fraction 
(25%, 25th and 75th percentiles of 20% and 26%), history of hypertension, and history of 
diabetes. Our patients were less often male, less often smokers, and less often had left 
bundle branch block. Our patients were less likely to have symptomatic congestive heart 
failure and to have had revascularizatlon procedures. After 3 years of follow-up, the 
Kaplan-Meier survival estimates for the Duke cohort and the conventional arm of the 
MADIT-II population were very similar (66% vs. 69%). Applying the observed benefit 
from an ICD in MADIT-II to our population showed that their extrapolated survival esti- 
mate was slightly lower than the observed survival estimate for the MADIT-II ICD arm 
(75% vs. 76%). Our patients’ mean life expectancy was 7.5 years without an ICD and 
11.2 years with an ICD. 
Conclusions: Our patients’ baseline characteristics and survival pattern were similar to 
those of patients enrolled in MADIT-II. As such, the results of MADIT-II seem to be appli- 
cable to patients seen at a tertiary referral center. 
1064-6 Antiarrhythmic Agents May Decrease Long-Term 
Survival in Patients With Implantable Defibrillators 
Hankrishna S. Tandri, Lawrence C. Griffith, Tama Tang, Khurram Nasir, Chandrasekhar 
Vasam Reddy. Gordon Tomaselk. Henly Halperin, Charles Leng, Ronald D. Berger, 
Hugh Calkins, Donahue J. Kevin, The Johns Hopkins University, Baltimore, MD 
Antiarrhythmic agents are increasingly used for arrhythmia control and to reduce the inci- 
dence of shocks in pattents receiving Implantable defibrillators (ICD). The effect of these 
drugs on long-term survival of ICD patients is unknown. We constructed a database of 
1037 consecutive ICD Implants performed at our institution from February 1960 to Sep- 
tember 1999. Baseline variables collected included; demographics implant indication, 
NYHA functional class, cardiac diagnosis. co morbidity, discharge medication, echocar- 
dlography and angiography results. Details of discharge antiarrhythmic drug was wall- 
able in 796 patients (76%), 434 (57%) received antiarrhythmic on discharge (157 on 
class I and 257 on class Ill) and 392 (43%) were discharged on no drug therapy. 46% of 
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the study population were discharged on beta blockers. During a mean follow-up of 67 
months (rangel- months) 602 deaths occurred in the study population. On multivari- 
ate analyses, patients discharged on antiarrhythmic medication had significantly higher 
mortality (hazard ratio 1.47, 95% Cl 1 .l l-l .97, p=O.O63) compared to those discharged 
on no drug therapy. Sub group analysis identtfied that the excess mortality was due to 
class Ill agents, Mortality in class I agents was no different than no drug therapy. Patients 
receiving beta-blockers had significantly less mortality (hazard ratio 0.44, 95% Cl 0.22- 
0.66, pcO.001) compared to those discharged on no beta blockade. In conclusion use of 
antiarrhythmic drugs may worsen long-term survival in the defibrillator populatton com- 
pared to no drug therapy. Use of beta-blockers was associated with significant survival 
advantage in this study. 
1064-19 Is Dofetilide Safe to Use in Patients With Implantable 
Cardioverter Defibrillators? 
Andrea M. Russq Hemal Nayak, Ralph J. Verdino, Henry Hsia. Ward Pulliam. Christina 
Morris, Lisa Ahlemeyer, Francis E. Marchlinski, University of Pennsylvania Health 
System, Philadelphia, PA 
1064-7 Eligibility for Biventricular Pacing in Patients With an 
Implantable Cardioverter Defibrillator 
Sander G. Molhoek, Jensen J. Bax, Lies&t van Erven. Marianne Bootsma, Paul 
Steendijk, Ernst E. van der Wall, Martin J. Schalij. L&den University Medical Center, 
Leiden, The Netherlands 
Background: Treatment of congestive heart failure (CHF) aims for symptomatic relief 
and reduction of mortality. An implantable cardiovetter defibrillator (ICD) prevents sud- 
den death in patients at high risk, whereas recent data suggest that biventricular (BV) 
pacing in patients with CHF may improve functional status. The combination of these 2 
treatments rnav be svnarctistic. It is unknown. however. which percentaae of patients with 
Background: Dofetilide (DOF) is a relatively new antiarrhythmic agent utilized for the 
treatment of atnal fibnllation. Although it has been studied in patients (pts) with underly- 
ing heart disease and left ventricular dysfunction, little data is available regarding its use 
tn pts with tmplantable cardiovetter defibrillators (ICDs) and known ventricular tachycar- 
dia (VT). 
Methods: We examined follow-up on 17 ICD pts treated with DOF for atrial fibrillation. 
Results: Mean age was 71 +/- 8 yrs, with 14 men, and mean LVEF 30 +/- 11%. Coronary 
disease was present in 12 pts and a nonischemic dilated cardiomyopathy in 5 pts. Indica- 
tions for ICD implantation include sustained VT or cardiac arrest in 10 pts. syncope in 6 
pts. and asymptomatic nonsustained VT with inducible VT in 1 pt. A history of congestive 
heart failure was noted in 12117 (71%) pts. Dosing was based on creatinine clearance 
and adjustments ware made based on the QT interval, as recommended by the mand- 
facturer. The defibrillation threshold (DFT) was 14.6 +/- 4.9 joules at baseline and 11 .l +I 
- 3.8 joules at follow-up on dofetilide (p=O.O7). The mean dofetilide dose was 662 +/- 305 
mcg/day. Mean follow-up was 209 +i- 202 days (median 82 days), and 9/17 (53%) 
remain in sinus rhythm on DOF. DOF was discontinued in 6 pts due to inefficacy, in 1 pt 
due to noncompliance, and in 1 pt due to nausea and a creatinine of 2.6. NO proarrhyth- 
mia was noted, and there were no drug-related deaths. 
Conclusions: DOF is well-tolerated and appears to be effective for the treatment of atrial 
fibrillation in ICD pts with underlying heart disease in short-term follow-up. Despite the 
preexisting history of ventricular arrhythmias, no adverse ventricular arrhythmias were 
noted in thus small group of pts. In addition, no detrimental effects on the DFT were 
noted. DOF may serve as an effective alternative to amiodarone in this pt population with 
less risk of end organ toxicity. 
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an ICD indication are potential candidates for BV pacing. 
Methods: All natients who received an ICD were analvzed for eliaibilitv of BV bacind 
Based on the available literature, established critena for BV pacing included NYHA class 
Ill or IV (z- 6 months) and a QRS duration z.120 ms. Patients in NYHA class II with a left 
ventricular ejection fraction (LVEF) ~30% and QRS z-120 ms were also considered eligt- 
ble. The incidence of potential exclusion criteria, including atrial fibrillation (AF), RBBB 
and PR interval ~150 ms, was also assessed. 
Results: 390 consecutive patients received an ICD from June 1996 till March 2001 at 
our hospital. There were 315 men and 75 women (mean age of 58 * 17 years). Underly- 
ing cardiac disease was ischemic hear-l disease (n=281, 72%) idiopathic dilated cardi- 
omyopathy (CM) (n=51, 13%) primary CM (n=31, ES), and miscellaneous in 7% (n=27) 
of the patients. Indications for ICD implantation were out hospital cardiac arrest (n=l99, 
51%). ventricular tachyarrhythmia (n=l72, 44%) and preventive (n=l9, 5%). In the 390 
patients the mean LVEF was 34 f 25%. The incidence of severe CHF (NYHA class III/IV) 
was 19% (74 pattents); 62 (16%) patients were in NYHA class II with an LVEF <30%. of 
these 136 patients, 70 had a QRS duration >120 ms (42 LBBB, 14 RBBB, 14 intraventric- 
ular conduction delay). Thus, a total of 70 (18%) patients ware eligtble for BV pacing in 
addition to an ICD. When patients either tn chronic AF or with RBBB were excluded, this 
number was reduced to 48 (12%). None of the patients had a PR tnterval<l50 ms (mean 
196 * 31ms, range 155 - 265). 
Conclusion: 12.18% of patients with an ICD indication are potential candidates for BV 
pacing. Screening for eltgtbtltty of BV pacing should be routinely considered in patients 
with CHF scheduled for ICD implantation. 
1064-6 Feasibility of Ventricular Resynchronization Coupled to 
an Atrial Arrhythmia Management Device 
David Schwartzman Atrtal Arrhythmia Center, Unwrsity of Pittsburgh, Pittsburgh, PA 
Background: Recent studies have demonstrated the value of biventricular pacing (biVP) 
in patients with CHF, diminished ejection fraction (EF), and left bundle branch block. 
These patients commonly have antiarrhythmic drug-resistant atrial fibrillation (DRAF). 
Optimal management may include atrial rhythm control. Previous studies in DRAF 
patients with preserved EF have demonstrated excellent long-term atrial rhythm control 
utilizing an atrial arrhythmia management device (AAMD). We hypothesized that an 
AAMD adapted to provtde btVP would be feasible and safe in carefully selected patients. 
Methods: In 20 patients with class II-IV CHF, EF<35%. left bundle branch block and 
DRAF with controlled ventncular response (16 men, ages 42-80 years. CAD in 13) an 
AAMD (Medtronic model 7250 [n=2] or 7276 [n=lE]) was implanted, coupled to right 
atrial appendage, right ventrtcular apical, and left venticular (epicardial [n=2]; trans- 
vents [n=lEt]) leads. For pactng and sensing, the ventricular leads were married by an 
adaptor (Medtrontc model 2872). Bradycardia programmtng was DDD or DDDR, with AV 
delays optimtzed ustng echocardrography. Ventricular tachyarrhythmia (VT) program- 
ming was stngle zone (median VT detection interval 280 msec). AF programming 
included “preventton pacing,” antitachycardia pacing, and patient-commanded shock. 
Previously inefficacious antiarrhythmic drug therapy was utilized as needed as an adju- 
vant rn patients to reduce AF burden. Results There were no implant complications. 
Durtng a followup interval ranging from 41 to 580 days, 7 patients have had AF events 
treated by the dewce; 5 patients have elicited shock, all without complication. Three 
patients are taking an anttarrhythmic drug. Two patients have undergone AV node abla- 
tion for uncontrollable AF burden. Single automatic shocks for device-perceived VT have 
been deftvered in 2 patients (one due to double- counted slow VT, the other due to elec- 
tromagnetic interference). Improvement of one or more HF class has been observed in 
13 patients; the remainder are unchanged. Conclusion: In selected patients, the cod- 
pling of an AAMD and biVP is feasible. In future systems, “srngle chamber” ventricular 
sensing is mandatory 
1064-20 Reliability and Clinical Benefits of a New Subthreshold 
Noninvasive Shock Lead Integrity Test 
Andreas Schuchert, Jochen Winter, Thomas Meinertz, Ludwig Binner, on behalf of the 
Reliance Investigators, University Hospital Hamburg-Eppendorf. Hamburg, Germany, 
Heine University, Diisseldorf, Germany 
Background: The integrity of the defibrillation lead is crucial for the proper function of 
implanted cardioverter / Uefibrillators. Serial measurements of the shock lead impedance 
are the most reliable non-invasive method to verify the integrity. The current approach is 
to deliver an at least 1 -J shock. As this is painful for the patient, deep sedation is manda- 
tory. The aim of the prospective study was to compare a new subthreshold measurement 
for shock lead impedance with the standard measurement. 
Methods: The study included 123 patients who received in 25 European centers either a 
Prism DR (n=73) or VR (n=50. Guidant. St. Paul, MN, USA) defibrillator. The deftbrillator 
was connected to the single coil (models 012710128; n = 39) or dual coil (models 0147/ 
0148; n = 84) Endotak Reliance defibrillation lead. The defibrillator delivers for the shock 
lead integrity test a cl mJ subthreshold pulse through the single coil or dual coil lead and 
the defibrillator housing (can). The current density of the test pulse is l/lOOth of a pacing 
pulse. Non-invasive shock lead impedance was measured for the defibrillation vectors 
from the distal coil to the proximal coil and can as well as from the distal coil to the can. 
The standard measurement for shock lead impedance was with a 17J shock. 
Results: The shock lead impedance for the vector from the distal coil to the proximal coil 
and the can was 42 * 5 ohms (95% confidence interval (Cl): 41 44 ohms) with the lead 
integrity test and and 41 * 4 ohms (*95% Cl: 39 43 ohms) with a high-energy shock (p 
= O.lS).The shock lead impedance for the vector from the distal coil to the can was 63 f. 
7 ohms (*95% Cl: 60 - 66) with the lead integrity test and 60 * 8 ohms (295% Cl: 56 - 64 
ohms) with a high-energy shock (p = 0.44). The vector from the distal coil to the can had 
a significant higher shock lead impedance than from the distal coil to the proximal coil 
and the can (p=O.OOl). 
Conclusion: The new subthreshold shock lead integrity test measured shock lead imped- 
ance similar to the standard measurement with the delivery of the high-energy shock. 
This non-invasive test is a useful diagnostic method as it allows serial measurements of 
the shock lead impedance during follow-up without the need for sedation. 
